Literature DB >> 21943668

Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Benjamin L Ebert1.   

Abstract

The 5q-syndrome is a subtype of myelodysplastic syndrome (MDS) with a defined clinical phenotype associated with heterozygous deletions of chromosome 5q. While no genes have been identified that undergo recurrent homozygous inactivation, functional studies have revealed individual genes that contribute to the clinical phenotype of MDS through haplo-insufficient gene expression. Heterozygous loss of the RPS14 gene on 5q leads to activation of p53 in the erythroid lineage and the macrocytic anemia characteristic of the 5q-syndrome. The megakaryocytic and platelet phenotype of the 5q-syndrome has been attributed to heterozygous deletion of miR145 and miR146a. Murine models have implicated heterozygous loss of APC, EGR1, DIAPH1, and NPM1 in the pathophysiology of del(5q) MDS. These findings indicate that the phenotype of MDS patients with deletions of chromosome 5q is due to haplo-insufficiency of multiple genes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21943668      PMCID: PMC3183434          DOI: 10.1053/j.seminoncol.2011.04.010

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  47 in total

Review 1.  Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.

Authors:  Aristoteles A N Giagounidis; Ulrich Germing; Carlo Aul
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

2.  The 5q- syndrome.

Authors:  A A N Giagounidis; U Germing; J S Wainscoat; J Boultwood; C Aul
Journal:  Hematology       Date:  2004-08       Impact factor: 2.269

Review 3.  The stem-cell niche as an entity of action.

Authors:  David T Scadden
Journal:  Nature       Date:  2006-06-29       Impact factor: 49.962

Review 4.  Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.

Authors:  Stephen D Nimer
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

5.  Role of nucleophosmin in embryonic development and tumorigenesis.

Authors:  Silvia Grisendi; Rosa Bernardi; Marco Rossi; Ke Cheng; Luipa Khandker; Katia Manova; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-07-06       Impact factor: 49.962

6.  Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia.

Authors:  Hanna T Gazda; Agnieszka Grabowska; Lilia B Merida-Long; Elzbieta Latawiec; Hal E Schneider; Jeffrey M Lipton; Adrianna Vlachos; Eva Atsidaftos; Sarah E Ball; Karen A Orfali; Edyta Niewiadomska; Lydie Da Costa; Gil Tchernia; Charlotte Niemeyer; Joerg J Meerpohl; Joachim Stahl; Gerhard Schratt; Bertil Glader; Karen Backer; Carolyn Wong; David G Nathan; Alan H Beggs; Colin A Sieff
Journal:  Am J Hum Genet       Date:  2006-11-02       Impact factor: 11.025

7.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

8.  The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.

Authors:  Lars Nilsson; Patrik Edén; Eleonor Olsson; Robert Månsson; Ingbritt Astrand-Grundström; Bodil Strömbeck; Kim Theilgaard-Mönch; Kristina Anderson; Robert Hast; Eva Hellström-Lindberg; Jan Samuelsson; Gösta Bergh; Claus Nerlov; Bertil Johansson; Mikael Sigvardsson; Ake Borg; Sten Eirik W Jacobsen
Journal:  Blood       Date:  2007-07-06       Impact factor: 22.113

9.  Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice.

Authors:  S Lehmann; J O'Kelly; S Raynaud; S E Funk; E H Sage; H P Koeffler
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

10.  Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders.

Authors:  John M Joslin; Anthony A Fernald; Thelma R Tennant; Elizabeth M Davis; Scott C Kogan; John Anastasi; John D Crispino; Michelle M Le Beau
Journal:  Blood       Date:  2007-04-09       Impact factor: 22.113

View more
  24 in total

1.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

Review 2.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

3.  Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.

Authors:  Angela Stoddart; Anthony A Fernald; Jianghong Wang; Elizabeth M Davis; Theodore Karrison; John Anastasi; Michelle M Le Beau
Journal:  Blood       Date:  2013-12-31       Impact factor: 22.113

4.  Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.

Authors:  Rebekka K Schneider; Monica Schenone; Monica Ventura Ferreira; Rafael Kramann; Cailin E Joyce; Christina Hartigan; Fabian Beier; Tim H Brümmendorf; Ulrich Germing; Uwe Platzbecker; Guntram Büsche; Ruth Knüchel; Michelle C Chen; Christopher S Waters; Edwin Chen; Lisa P Chu; Carl D Novina; R Coleman Lindsley; Steven A Carr; Benjamin L Ebert
Journal:  Nat Med       Date:  2016-02-15       Impact factor: 53.440

5.  Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells.

Authors:  Kilannin Krysiak; Justin F Tibbitts; Jin Shao; Tuoen Liu; Matthew Ndonwi; Matthew J Walter
Journal:  Exp Hematol       Date:  2014-12-27       Impact factor: 3.084

6.  MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways.

Authors:  Minyoung Youn; Haigen Huang; Cheng Chen; Sharon Kam; Mark C Wilkes; Hee-Don Chae; Kunju J Sridhar; Peter L Greenberg; Bertil Glader; Anupama Narla; Shuo Lin; Kathleen M Sakamoto
Journal:  Blood Adv       Date:  2019-09-24

Review 7.  The progress of early growth response factor 1 and leukemia.

Authors:  Jing Tian; Ziwei Li; Yang Han; Tao Jiang; Xiaoming Song; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2016-05

Review 8.  The molecular mechanism of thalidomide analogs in hematologic malignancies.

Authors:  Stefanie Lindner; Jan Krönke
Journal:  J Mol Med (Berl)       Date:  2016-08-05       Impact factor: 4.599

9.  Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc.

Authors:  Angela Stoddart; Jianghong Wang; Anthony A Fernald; Theodore Karrison; John Anastasi; Michelle M Le Beau
Journal:  Blood       Date:  2013-11-21       Impact factor: 22.113

10.  Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Authors:  Rebekka K Schneider; Vera Ademà; Dirk Heckl; Marcus Järås; Mar Mallo; Allegra M Lord; Lisa P Chu; Marie E McConkey; Rafael Kramann; Ann Mullally; Rafael Bejar; Francesc Solé; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2014-09-18       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.